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Abstract
Background: Medications from Anthroposophical Medicine (AM) are clinically used for the treatment of infections
within a whole medical system but have not yet been evaluated regarding antibacterial effects. The aims of this
study was to investigate antibacterial activity of AM medications in cell culture.
Methods: Screening of AM drug registers for preparations used to treat any kind of infection and being available in
dilutions ≤ D2 and without alcoholic content. Selected medications were screened for antimicrobial activity against
Bacillus subtilis, Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa using the agar diffusion method.
For antimicrobial active preparations growth kinetics (drop plate method) and minimal inhibitory concentrations
(MIC, macrodilution method) were determined.
Results: Thirty-three preparations matched the selection criteria and were chosen for own experiments. One of
them (Berberis Decoctum D2) exhibited bactericidal activities against Bacillus subtilis and Staphylococcus aureus,
including methicillin resistant strains. The MIC could be determined as 5 mg/ml. The effects could be related to the
content of berberine in the extract. No activity towards gram-negative bacteria was found. The other tested extracts
had no antibacterial effects.
Conclusion: Berberis Decoctum D2 which is used in AM to treat infections exhibits bactericidal effects on
Staphylococcus aureus, including methicillin resistant strains.
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Background
Antimicrobial resistance is one of the major problems of
modern medicine. Considering the fast development of
resistance to antibiotics in bacterial species such as
Mycobacterium tuberculosis [1] or Staphylococcus aures
[2], it becomes obvious that there is necessity to combat
further resistance expansion [3]. However there is a con-
cerning stagnation in the development of new antimicro-
bial agents [4] although more and more mechanisms of
bacterial resistance are being discovered. For the pur-
pose of developing new antimicrobial agents natural
substances should be considered as a promising source
[5]. Besides traditional antibiotics of microbial origin like
penicillin, there is clear evidence that plant-derived
preparations have antimicrobial potential [6]. They are able
to synergize traditional antibiotics and therefore reduce the
required dosage for infection control [7, 8] and there is evi-
dence that plant-derived preparations are able to modify
mechanisms of resistance [5, 9]. Examples for commonly
used phytotherapeutics in infection control are the root ex-
tracts from Pelargonium sidoides in the treatment of the
common cold [10] or Horseradish and Tropaeolum in the
treatment of urinary or respiratory infections [11–13]. An-
other focus of current research is the role of bacteria for
the health of the human body. Referred to as the Human
Microbiome it is evident today that those billions of mi-
crobes, especially located in the human gut, play a decisive
role in the strengthening of health and a balanced immune
system [14]. The pathogenesis of the metabolic syndrome
[15] as well as allergic and autoimmune disorders such as
bronchial asthma [16] or inflammatory bowel diseases
[17, 18] is nowadays considered to be at least in part re-
lated to the human microbiome and especially to the gut
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microbiota. Antibiotics are well-known for their hurtful
effects on this sensitive system of intestinal microflora. It
is not uncommon that patients need microflora recon-
struction after broad-spectrum antibiotic treatment. In this
regard it is particularly interesting to examine substances
with selective effects on the gut microflora or on bacterial
strains in general: substances which have the characteristic
of combatting harmful microbes but spare the physio-
logical flora or even supporting and protecting it. Therein
lies another possible role of plant-based antimicrobials in
contrast to conventionally used antibiotics. Usually their
potency isn’t as resounding that they would eradicate the
majority of microbes of intestinal microflora and therefore
provide niches for selectivity and protective potential.
Drugs from Anthroposophical Medicine (AM) have to
our knowledge not yet been explored regarding their anti-
microbial effects. Their manufacturing process is sophisti-
cated and often different from manufacturing process in
phytotherapy [19]. They are amongst others used to treat
infectious diseases, despite they are not claimed to possess
antimicrobial effects. They are instead designed to im-
prove the self-healing capacity of the body in these dis-
eases [20]. Nevertheless they are a possible source of new
types of antimicrobial compounds. Preparations of AM
are traditionally being used in German-speaking areas.
The drug compendia contain approximately 1500 different
medicinal products including plant-based, animal-based,
mineral and combined preparations [21, 22]. The aim of
this study was to investigate the antimicrobial potential of
plant-based preparations of AM.
Methods
Compendia of drugs from Anthroposophical drug manu-
facturers [21, 22] have been searched for preparations in
dilutions ≤D2 and free of alcoholic content. Higher dilu-
tions have been excluded in order to guarantee that the
preparations contained active substances. Alcoholic con-
tent was not accepted because it exhibits antimicrobial
effects itself. Preparations with more than one plant have
also been excluded in order to observe merely the effects
of individual plants. Out of the remaining preparations
those were chosen for proper experiments which were
used for the treatment of infections in AM.
Bacterial strains used for antimicrobial assays
Bacillus subtilis (ATCC 6633), Escherichia coli (ATCC
25922), Methicillin-susceptible Staphylococcus aureus
(MSSA, ATCC 29213), Pseudomonas aeruginosa (ATCC
27853), Methicillin-resistant Staphylococcus aureus (MRSA,
ATCC 43300) and clinical isolates of MSSA (MSSA 1883,
2114, 2289) and MRSA (MRSA 4331) from the Hygiene
and Molecular Laboratory of the Institute of Environmental
Health Sciences and Hospital Infection control of the
University Medical Center, Freiburg, Germany were
chosen for own experiments.
Activity screening following the agar diffusion method
A bacterial suspension of one of the microbial strains listed
above was produced in isotonic saline solution by visual
comparison to a 0.5 McFarland turbidity standard (bio-
Mérieux, Germany). This standard corresponds to a con-
centration of 108 colony forming units (CFU)/ml. This
solution was used to prepare bacterial smears in three
layers on Columbia Blood Agar plates (Thermo Scientific,
Great Britain). The test substances were then brought onto
the bacterial layer in drops of 10 μl at defined positions.
The agar plates were incubated for 24 hours at 37 °C.
Growth Kinetics following the drop plate method
An overnight culture was prepared the day before by solv-
ing 1-3 colonies of a bacterial strain in 5 ml of Mueller-
Hinton broth (MHB) (Merck KGaA, Germany) and by
incubating this solution for 24 hours at 37 °C in a shaker
(Certomat® ; B Braun, Germany) at an intensity of 100 t/
min. The overnight culture was then set to a concentration
of 108 CFU/ml in a Turbiditymeter (Micro Scan, US) and
diluted to a concentration of 106 CFU/ml. Control and test
samples were prepared by mixing 1000 μl of double-
concentrated MHB and 1000 μl of distilled water (control)
or 1000 μl of the test substance, respectively. 20 μl of bac-
terial suspension of 106 CFU/ml were finally added to con-
trol and test samples. Up to six samples could be handled
simultaneously. All samples were distributed into airtight
Eppendorf tubes by pipetting 200 μl of each sample into
eight Eppendorf tubes (two, each for 0, 4, 8 and 24 hours
incubation). The 4, 8- and 24-hour-Eppendorf tubes were
incubated at 37 °C in a shaker (Certomat®; B Braun,
Germany) at an intensity of 100 t/min. The 0-hour-
Eppendorf tubes were serially diluted with Mueller-Hinton
broth using a microtiter plate. 5 μl of each concentration
was afterwards pipetted onto Mueller-Hinton Agar-Plates
(Merck KGaA, Germany). Five to six dilution steps fit the
agar plate properly. In the same way was dealt with the t4-,
t8- and t24-eppendorf tubes after the particular incubation
times. All Mueller-Hinton-Agar-Plates were incubated at
37 °C for 24 hours. After 24 hours single colonies of bac-
terial growth could be counted in the areas where the
former 5 μl-drops have been put on the Mueller-Hinton-
Agar-Plate. The counted colonies yielded a specific growth
value for each sample and incubation time.
Determination of the Minimal Inhibitory Concentration (MIC)
The MIC was determined in CAMHB (Cation Adjusted
Mueller-Hinton Broth) according to the guidelines of CLSI
in macrodilution-method. For Berberis Decoctum D2 a ser-
ial dilution has been performed with a concentration of
5 mg/ml in the first and a final concentration of 9.8 μg/ml
Roser et al. BMC Complementary and Alternative Medicine  (2016) 16:372 Page 2 of 7
in the last tube. The initial concentration of bacteria was
set to 106 CFU/ml and was diluted to 105 CFU/ml in the
samples. The samples were incubated at 36 °C and the
MIC was determined as the lowest concentration without
visible bacterial growth after 24 hours of incubation.
Statistics
All experiments on bacterial strains which play a major role
in human infections and showed noteworthy effects after
24 hours have been carried out at least twice on the same
bacterial strain or different clinical isolates of one bacterial
species. Because the growth of bacteria in a growth kinetic
assay varies to a small extend between different experi-
ments an inhibitory effect was defined as the difference of
at least 1 logarithmic unit between test sample and control.
Thus only marked differences of growth were included.
Results and Discussion
Eighty four preparations with a total of 54 different in-
gredients matched the inclusion criteria and have been
selected out of the Anthroposophical drug registers. 33
of those were then chosen for proper experiments be-
cause they were either used for infection control in AM
Table 1 Preparations of AM with botanical name and dosage form which were chosen for proper experiments
Botanical name listed preparation of AM dosage form
Arnica montana Arnica e planta tota (Arnica montana e planta tota ferm 33c) D2 preparation for injection
Astragalus exscapus Astragalus exscapus D3 preparation for injection
Belladonna Belladonna Rh D3 aqueous solution
Berberis vulgaris Berberis, Decoctum D2 preparation for injection
Berberis, Fructus Rh D2 preparation for injection
Betula pendula Betula, Cortex, Decoctum D2 preparation for injection
Bryonia cretica Bryonia D3 preparation for injection
Bryophyllum Bryophyllum 5 % preparation for injection
Selenicereus grandiflorus Cactus ex herba (Selenicereus grandiflorus ex herba ferm 33d) D2 preparation for injection
Cinnamomum camphora Camphora (Camphora aquos.) D3 preparation for injection
Cetraria islandica Cetraria praeparata (Cetraria islandica) 2 % preparation for injection
Chamomilla recutita Chamomilla, Radix, Decoctum D3 preparation for injection
Cichorium intybus Cichorium Rh D3 aqueous solution
Cydonia oblonga Cydonia e fructibus (Cydonia oblonga e fructibus ferm 33b) D2 preparation for injection
Echinacea angustifolia Echinacea angustifolia Rh D3 preparation for injection
Echinacea e planta tota (E. pallida e planta tota ferm 33c) D2 preparation for injection
Gentiana lutea Gentiana lutea Rh 5 % aqueous solution
Geum urbanum Geum urbanum e radice (WS: G.u. e radice ferm 33c) D3 preparation for injection
Geum urbanum e radice D1 mother tincture
Levico Levico (Levico water) D3 preparation for injection
Levisticum Levisticum Rh D3 aqueous solution
Mandragora officinarum Mandragora officinarum e radice ferm 34d, D2 preparation for injection
Nicotiana tabacum Nicotiana e foliis (Nicotiana tabacum e foliis ferm 33b) D2 preparation for injection
Oxalis acetosella Oxalis, Folium Rh D3 preparation for injection
Prunus spinosa Prunus spinosa, Fructus Rh D3 preparation for injection
Prunus spinosa, Summitates Rh D3 preparation for injection
Rosmarinus officinalis Rosmarinus, Infusum 5 % preparation for injection
Urginea maritima Scilla e bulbo (Urginea maritima var. Rubra e bulbo ferm 33b) D2 preparation for injection
Solidago virgaurea Solidago virgaurea ex herba (S. virgaurea ex herba ferm 33c) D3 preparation for injection
Solidago virgaurea ex herba D1 mother tincture
Symphytum officinale Symphytum e radice (S. officinale e radice ferm 34c) D2 preparation for injection
Taraxacum officinale Taraxacum e planta tota (T. officinale e planta tota ferm 34c) D3 preparation for injection
Taraxacum e radice (autumnale) (T.off. e radice ferm 34c) D3 preparation for injection
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or because they were available in dilutions ≤D2 (Table 1).
It can be assumed that the majority of all available and
eligible preparations have been screened.
Out of the 33 preparations screened with the agar diffu-
sion method, four (Berberis Decoctum D2, Betula Cortex
Decoctum D2, Solidago virgaurea Mother Tincture and
Geum urbanum Mother Tincture) showed antimicrobial
effects. The antimicrobial activity of the mother tinctures
Solidago virgaurea and Geum urbanum could be related to
their pH-values (3.5 and 5.0, respectively). In a buffered
assay with a neutral pH (7) the antimicrobial activity
vanished. The two tinctures were therefore excluded from
further experiments. It is advisable to determine the pH of
plant-based preparations routinely before performing
Fig. 1 Berberis Decoctum D2 – effects on bacterial growth after 0, 4, 8 and 24 hours on logarithmic scale. Control sample: distilled water (DW);
test sample: Berberis Decoctum D2. Control sample and test sample were added in a ratio of 1:2 to the culture medium. Effects are visible for B.
subtilis (ATCC 6633) (n = 1) and MSSA (ATCC 29213) (n = 3) after eight and after 24 hours. Effects can be considered as bactericidal. No relevant
effects after 24 hours could be found for E. coli (n = 1) and P. aeruginosa (n = 1)
Roser et al. BMC Complementary and Alternative Medicine  (2016) 16:372 Page 4 of 7
antimicrobial assays [6], not only because acidity itself
has effects on bacterial growth behavior but also be-
cause it influences the impacts of active ingredients
in preparations [23].
All further experiments have been performed using
the drop plate method. Berberis Decoctum D2 exhibited
bactericidal effects on B. subtilis and MSSA (ATCC
29213) as shown in Fig. 1. Betula Cortex Decoctum D2
did not show any noteworthy effects and was therefore
excluded from further experiments.
The bactericidal impact of Berberis Decoctum D2
could be confirmed by demonstrating the same effects
on clinical isolates of MSSA (abscess-associated 1883,
catheter-associated 2114, wound swab 2289) and on one
clinical isolate of a multi-drug resistant strain MRSA
(wound swab 4331). Because B. subtilis plays no major
Fig. 2 Effects on bacterial growth of Staphylococcus aureus strains (clinical isolates, each n = 1) after 0, 4, 8 and 24 hours on logarithmic scale.
Control sample distilled water (DW) and test sample Berberis Decoctum D2 were added in a ratio of 1:2 to the culture medium. Bactericidal
effects are visible for all S. aureus strains
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role in human infections further experiments were fo-
cused on S. aureus strains.
Figure 2 shows the same outcomes for all tested S. aur-
eus strains including one multi-drug resistant strain.
Berberis Decoctum D2 is manufactured from the bark and
roots of Berberis vulgaris and contains the alkaloid berber-
ine which has been described as antimicrobial active in
several publications [24]. According to the manufacturers
information one ampoule of Berberis Decoctum D2 con-
tains 10 mg of the dried drug of Berberis cortex and the
bark used for manufacture of the injectable contains at
least 2 % of alkaloids which can be mainly considered as
berberine. During growth kinetics Berberis Decoctum D2
was used in a concentration of 1:2 to the culture medium,
which equals a dosage of 5 mg/ml of the dried drug in the
experiment. For MSSA (ATCC 29213) and MRSA (ATCC
43300) the MIC could be determined as 5 mg/ml. A lower
dosage wasn’t able to exhibit bactericidal effects. The MIC
values of pure berberine for MSSA (ATCC 29213) and
MRSA (ATCC 43300) were 64 μg/ml and 256 μg/ml,
respectively. These values equal approximately the pro-
claimed concentration of berberine in the injectable
Berberis Decoctum D2 (100 μg/ml). It can, therefore, be
assumed that the effects of Berberis Decoctum D2 are due
to the content of berberine.
Compared to common antibiotics, the concentrations
of Berberis Decoctum D2 needed for bactericidal effects
are considerably higher. Interesting for systemic usability
would be a concentration <100 μg/ml for plant extracts
or <10 μg/ml for isolated compounds [6]. In an assay re-
vealing the effects of Berberis Decoctum D2 on human
lymphocytes we found that Berberis Decoctum D2 is in-
ducing apoptosis in about 70 % of lymphocytes if applied
in a concentration of 5 mg/ml (MIC results not shown).
Systemic application in a bactericidal dosage of 5 mg/ml
would therefore be toxic. In AM, however, the prepar-
ation is injected subcutaneously, close to the infected
areas, e.g. around the paranasal sinuses to treat sinusitis
[20]. This application might indeed induce brief antibac-
terial concentrations in the subcutaneous tissues. It re-
mains an open question, whether this is relevant for the
treatment with this medication and weather it improves
healing properties according to the concepts of AM.
The antimicrobial effects of Berberis Decoctum D2 were
selective. It worked on strains of S. aureus and B. subtilis,
but spared the gram-negative strains of E. coli and P. aeru-
ginosa. It would therefore be interesting to examine the ef-
fects of Berberis Decoctum D2 on strains of the human
gut flora and emphasize on selective effects in terms of a
destruction of harmful germs and simultaneous sparing of
protective species. For berberine-chloride, obtained from
the roots of Coptis japonica, such a positive selectivity on
germs of the intestinal flora has already been reported
[25]. Furthermore it would be interesting to examine the
effects of a topical application of Berberis Decoctum D2,
especially in case of colonization with multi-resistant S.
aureus strains. For this purpose Berberis Decoctum D2
could be applied in concentrations higher than the deter-
mined MIC of 5 mg/ml. Synergistic effects of Berberis
Decoctum D2 to antibiotics have not yet been investi-
gated. Such synergistic effects have been reported repeat-
edly for different plant derived substances [7, 26, 27].
Regarding the fact that Berberis Decoctum D2 has, in
contrast to berberine, the status of an approved drug
in Germany, investigations using this plant extract
would be worthwhile.
Conclusions
Our investigations revealed that Berberis Decoctum D2
has bactericidal effects on Staphylococcus aureus, includ-
ing methicillin resistant strains, which might be clinically
useful in local application.
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